© 1999 by European Society of Cardiology
Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil
Department of Cardiology, Lund University Lund, Sweden; *Department of Applied Electronics, Lund Institute of Technology Lund, Sweden
AIMS: Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil.
METHODS AND RESULTS: Thirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147±13 ms to 156±21 ms after 1 day (P=0·02), to 164±18 ms after 5 days (P=0·005) and finally to 160±16 ms after 6 weeks (P=0·008).
CONCLUSION: Long-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF.
Key Words: Atrial fibrillation, remodelling, verapamil, arrhythmia, Ca-channel
Correspondence: Dr Carl J. Meurling, Department of Cardiology, University Hospital, SE-221 85 Lund, Sweden.
[1] Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29: 469–489.
[2] van Gelder IC, Crijns HJ, van Gilst WH. Prediction of uneventful cardioversion and maintenance of sinus rhythm from Direct-Current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41–46.[Web of Science][Medline]
[3] Horowitz LN, Spielman SR, Greenspan AM. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402–1407.[Abstract]
[4] Suttorp MJ, Kingma JH, Jessurun ER, Lie-a-huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–1727.[Abstract]
[5] Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634–638.
[6] Morris JJ, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation. Ann Intern Med 1966; 65: 216–231.
[7] Resnekov L and McDonald L. Appraisal of electroconversion in treatment of cardiac dysrhythmias. Br Heart J 1968; 30: 786–811.
[8] Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124–127.[CrossRef][Web of Science][Medline]
[9] Crijns HJ, van Gelder IC, van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335–341.[CrossRef][Web of Science][Medline]
[10] Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. British Heart Journal 1971; 33: 518–521.
[11] Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284–290.
[12] Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and flutter. J Am Coll Cardiol 1988; 12: 1005–1011.[Abstract]
[13] Crijns HJ, Gosselink ATM, Lie KI. for the PRODIS Study group. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study. Cardiovasc Drugs Ther 1996; 10: 145–152.[CrossRef][Web of Science][Medline]
[14] Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanism. Circulation 1996; 94: 2968–2974.
[15] Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Circulation 1996; 94: 2953–2960.
[16] Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997; 30: 1785–1792.[Abstract]
[17] Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954–1968.
[18] Tieleman RG, De Langen C, van Gelder IC. Verapamil reduces tachycardia-induced electrical remodelling of the atria. Circulation 1997; 95: 1945–1953.
[19] Daoud EG, Knight BP, Weiss R. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96: 1542–1550.
[20] Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand 1971; 190: 381–387.[Web of Science][Medline]
[21] Brorson L and Olsson B. Right monophasic action potential in patients with paroxysmal supraventricular tachyarrhythmias. Acta Med Scand 1977; 201: 105–110.[Web of Science][Medline]
[22] Lammers WJEP, Allessie MA, Rensma PL, Schalij MJ. The use of fibrillation cycle length to determine spatial dispersion in electrophysiological properties and to characterize the underlying mechanism of fibrillation. N Trends Arrhyth 1986; 1: 109–112.
[23] Misier AR, Opthof T, van Hemel NM. Increased dispersion of ‘refractoriness’ in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531–1535.[Abstract]
[24] Capucci A, Biffi M, Boriani G. Dynamic electrophysiological behaviour of human atria during paroxysmal atrial fibrillation. Circulation 1995; 92: 1193–1202.
[25] Kim KB, Rodefeld MD, Schuessler RB, Cox JL, Boineau JP. Relationship between local atrial fibrillation interval and refractory period in the isolated canine atrium. Circulation 1996; 94: 2961–2967.
[26] Holm M, Pehrson S, Ingemansson M. Noninvasive assessment of the atrial cycle length during atrial fibrillation in man. Introducing, validating and illustrating a new ECG method. Cardiovasc Res 1998; 38: 69–81.
[27] Ingemansson MP, Holm M, Olsson SB. Autonomic modulation of the atrial cycle length by the head up tilt test: non-invasive evaluation in patients with chronic atrial fibrillation. Heart 1998; 80: 71–76.
[28] Pehrson S, Holm M, Meurling C. Noninvasive assessment of magnitude and dispersion of atrial cycle length during chronic atrial fibrillation in man. Eur Heart J 1998; 19: 1836–1844.
[29] Stridh M and Sornmo L. Improved QRST cancellation techniques with application to atrial fibrillation analysis. In Murray A and Swiryn S (Eds.). Computers in cardiologyCleveland, Ohio IEEE pp. 633–6.
[30] In Dollery C (Ed.). Therapeutic Drugs 1991; Edinburgh Churchill Livingstone.
[31] Robertson RM and Robertson D. Drugs used for the treatment of myocardial ischemia. In Hardman JD, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (Eds.). Goodman & Gilman's The pharmacological basis of therapeutics 1995; New York McGraw-Hill pp. 766–74.
[32] Singh BN and Nademanee K. Use of calcium antagonists for cardiac arrhythmias. Am J Cardiol 1987; 59: 153B–162B.[CrossRef][Medline]
[33] Rosen MR, Wit AL, Hoffman BF. Appraisal and reappraisal of cardiac therapy. Electrophysiology and pharmacology of cardiac arrhythmias. Cardiac effects of verapamil. Am Heart J 1975; 89: 665–673.[CrossRef][Web of Science][Medline]
[34] Boucher M, Dubray C, Duchene-Marullaz P. Effects of bepridil, diltiazem and verapamil on atrial refractoriness and heart rate in the conscious dog: comparison with quinidine. Gen Pharmacol 1991; 22: 581–587.[Web of Science][Medline]
[35] Lai W, Voon W, Yen H. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 71: 405–408.[CrossRef][Web of Science][Medline]
[36] Ramanna H, Elvan A, Hauer RN. Verapamil causes increase in dispersion and shortening of refractoriness in human chronic atrial fibrillation (Abstr). PACE 1998; 21: 51.
[37] Duytschaever M, Mast F, Allessie M. Pro-fibrillatory effects of verapamil in a goat model of atrial fibrillation (Abstr). PACE 1998; 21: 199.
[38] Zipes DP. Electrophysiological remodeling of the heart owing to rate. Circulation 1997; 95: 1745–1748.
[39] Tieleman RG, van Gelder IC, Crijns HJGM. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria. J Am Coll Cardiol 1998; 31: 167–173.
[40] Wijffels MCEF, Kirchhof CJHJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats. Circulation 1997; 96: 3710–3720.
[41] Bayer R, Kalusche D, Kaufmann R, Mannhold R. Inotropic and electrophysiological actions of verapamil and D600 in mammalian myocardium III. Effects of the optical isomers on transmembrane action potentials. Naunyn Schmiedebergs Arch Pharmacol 1975; 290: 81–97.[CrossRef][Web of Science][Medline]
[42] Singh BN and Vaughan Williams EM. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on features on cardiac function. Cardiovasc Res 1972; 6: 109–119.[Web of Science][Medline]
[43] Cranefield PF, Aronson RS, Wit AL. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac purkinje fibers. Circulation Res 1974; 34: 204–213.
[44] Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535–1540.[Abstract]
[45] Leistad E, Verburg G, Christensen G. Cytosolic calcium overload, not atrial ischemia, accounts for post-fibrillation atrial dysfunction (Abstr). Circulation 1994; 90: I–492.
[46] Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation 1996; 93: 1747–1754.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Sornmo, M. Stridh, D. Husser, A. Bollmann, and S. B. Olsson Analysis of atrial fibrillation: from electrocardiogram signal processing to clinical management Phil Trans R Soc A, January 28, 2009; 367(1887): 235 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson Fibrillatory rate response to candesartan in persistent atrial fibrillation Europace, October 1, 2008; 10(10): 1138 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Niwano, H. Fukaya, T. Sasaki, Y. Hatakeyama, A. Fujiki, and T. Izumi Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring Europace, December 1, 2007; 9(12): 1209 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bollmann, D. Husser, L. Mainardi, F. Lombardi, P. Langley, A. Murray, J. J. Rieta, J. Millet, S. B. Olsson, M. Stridh, et al. Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications. Europace, November 1, 2006; 8(11): 911 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Holmqvist, M. Stridh, J. E.P. Waktare, L. Sornmo, S. B. Olsson, and C. J. Meurling Atrial fibrillatory rate and sinus rhythm maintenance in patients undergoing cardioversion of persistent atrial fibrillation Eur. Heart J., September 2, 2006; 27(18): 2201 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Holmqvist, M. Stridh, J. E.P. Waktare, A. Roijer, L. Sornmo, P. G. Platonov, and C. J. Meurling Atrial fibrillation signal organization predicts sinus rhythm maintenance in patients undergoing cardioversion of atrial fibrillation Europace, August 1, 2006; 8(8): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Holmqvist, M. Stridh, J. E. P. Waktare, J. Brandt, L. Sornmo, A. Roijer, and C. J. Meurling Rapid fluctuations in atrial fibrillatory electrophysiology detected during controlled respiration Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H754 - H760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-J A Lindholm, O Fredholm, S-J Moller, N Edvardsson, T Kronvall, T Pettersson, V Firsovaite, A Roijer, C J Meurling, P G Platonov, et al. Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil Heart, May 1, 2004; 90(5): 534 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Manios, E. M. Kanoupakis, G. I. Chlouverakis, M. D. Kaleboubas, H. E. Mavrakis, and P. E. Vardas Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence Cardiovasc Res, August 1, 2000; 47(2): 244 - 253. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||